Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425826 · ClinicalTrials.gov registry record · Phase 4
A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
A Phase 4 study of Parapsoriasis, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 221
- Enrollment target
- 20
- Study locations
NCT02425826: Completed Phase 4 study of Parapsoriasis, sponsored by Amgen.
NCT02425826 is a Phase 4 study of Parapsoriasis that has completed, run by Amgen. The registered enrollment target is 221 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02425826, a Phase 4 study of Parapsoriasis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 221 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the Extension Phase of the trial.
Primary Outcome
BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. The sPGA is a 6-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), 5 (very severe) incorporating a separate assessment of the severity of the three primary signs of the plaques of all involved ar
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Apremilast
- DRUG Placebo-Apremilast
Study Locations (20)
California
- Center For Dermatology - Fremont
- Dermatology Research Associates - Los Angeles
- Blue Harbor Dermatology - Newport Beach
- Center for Dermatology and Laser Surgery - Sacramento
- East Bay Rheumatology Medical - San Leandro
- Tien Q. Nguyen MD Inc - Tustin
Florida
- Dermatology Associates - Panama City
- USF Health Faculty Office Building-FOB - Tampa
- Forward Clinical Trials Inc - Tampa
Kentucky
- Dermatology Specialists, PSC - Louisville
- DermResearch, PLLC - Louisville
Alabama
- UAB at Birmingham - The Kirklin Clinic - Birmingham
Connecticut
- UConn Health Center - Farmington
Georgia
- Dermatologic Surgery Specialists, P.C. - Macon
Indiana
- Shideler Clinical Research Center - Carmel
Maryland
- Lawrence Green, MD, LLC - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2015-04-20 |
| Est. Completion | 2016-11-22 |
| Phase | Phase 4 |
What the finished NCT02425826 record still lists
NCT02425826 is an interventional study that assigns participants to a tested intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Parapsoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02425826 names 20 study sites across 12 states, led by California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT02425826 about?
NCT02425826 is a clinical study titled "A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.". This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the Extension Phase of the tri...
What is the current status of trial NCT02425826?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 221 participants. The study started on 2015-04-20. Estimated completion is 2016-11-22.
What conditions does trial NCT02425826 study?
This clinical trial studies the following conditions: Parapsoriasis.
What interventions are being tested in trial NCT02425826?
The interventions under investigation include: Placebo (DRUG), Apremilast (DRUG), Placebo-Apremilast (DRUG).
Who is sponsoring clinical trial NCT02425826?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02425826 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02425826's enrollment target sits among peer trials
221 383rd of 2000 higher than 1,617 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03170440 · 221 participants · NA
Non-invasive Nerve Stimulation for PTSD and Sleep
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI